Top Page
ANGLE plc
(LSE:AGL)
ANGLE plc (AGL) vs. iShares MSCI United Kingdom ETF (EWC)
ANGLE plc Business Overview & Revenue Model
ANGLE plc Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.86M | 2.19M | 1.04M | 1.01M | 762.00K |
| Gross Profit | 1.78M | -408.00K | 613.00K | 711.00K | 597.00K |
| EBITDA | -13.02M | -19.48M | -22.06M | -15.74M | -12.29M |
| Net Income | -14.22M | -20.13M | -21.69M | -15.01M | -11.61M |
Balance Sheet | |||||
| Total Assets | 25.46M | 31.18M | 49.87M | 47.31M | 39.05M |
| Cash, Cash Equivalents and Short-Term Investments | 10.43M | 16.22M | 31.90M | 31.84M | 28.62M |
| Total Debt | 4.21M | 4.55M | 5.00M | 2.34M | 1.36M |
| Total Liabilities | 7.02M | 8.24M | 9.80M | 6.99M | 4.71M |
| Stockholders Equity | 18.44M | 22.94M | 40.06M | 40.33M | 34.34M |
Cash Flow | |||||
| Free Cash Flow | -13.89M | -15.12M | -17.94M | -15.80M | -8.35M |
| Operating Cash Flow | -13.45M | -14.46M | -16.05M | -14.01M | -7.85M |
| Investing Cash Flow | -48.00K | -203.00K | -1.75M | 14.77M | -1.97M |
| Financing Cash Flow | 7.67M | -1.13M | 18.10M | 18.99M | 18.14M |
ANGLE plc Technical Analysis
ANGLE plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | £11.13M | ― | -62.83% | ― | 27.60% | 1.35% | |
51 Neutral | $7.91B | -0.36 | -41.71% | 2.23% | 23.45% | -1.86% | |
51 Neutral | £3.28M | ― | -321.90% | ― | 125.37% | 22.47% | |
49 Neutral | £24.19M | ― | -68.75% | ― | 30.92% | 36.40% | |
47 Neutral | £10.24M | ― | ― | -2.80% | -38.55% | ||
46 Neutral | £4.02M | ― | -367.05% | ― | 25.05% | 65.30% | |
45 Neutral | £7.95M | ― | -130.73% | ― | 226.45% | 53.51% |
ANGLE plc Corporate Events
ANGLE plc announced a significant publication in Nature Genetics, highlighting the use of its Parsortix system to study the genetic diversity of circulating tumor cell (CTC) clusters. This research, conducted by Professor Nicola Aceto’s team, underscores the importance of CTC clusters in cancer progression and metastasis, revealing that these clusters are key contributors to genetic diversity and therapy resistance. The findings suggest that targeting CTC clusters could be crucial in halting cancer spread, as they are significantly more metastatic than individual CTCs, which has profound implications for cancer treatment strategies.
The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
ANGLE plc presented new data at the EACR 2025 Congress, highlighting its DNA dual analysis approach using the Parsortix system in collaboration with Illumina. The study demonstrated the system’s ability to reveal tumour heterogeneity in lung cancer patients by analyzing both CTC-DNA and ctDNA, offering valuable insights for biopharma partners in identifying drug targets and improving trial outcomes.
The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
ANGLE plc has presented new data at the European Association for Cancer Research (EACR) Congress, showcasing a novel assay for profiling androgen receptor expression in metastatic prostate cancer. This assay, developed using the Parsortix system, addresses a significant unmet need by enabling sensitive, real-time monitoring of androgen receptor activity, which is crucial for assessing treatment response in prostate cancer trials. The assay’s potential utility for pharmacodynamic assessment could significantly impact the market, which is projected to reach a value of $9.8 billion by 2032, by providing a tool for monitoring drug response and resistance in real-time.
The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
ANGLE plc announced the publication of three peer-reviewed studies utilizing its Parsortix system to explore cancer biology and potential therapeutic targets. These studies highlight the system’s role in advancing understanding of tumor cell release during surgery and metastatic progression, offering insights that could guide future cancer treatment strategies. The findings underscore the potential of ANGLE’s technology to contribute to personalized cancer diagnostics and therapeutics, as academic and translational research continue to drive innovation in oncology.
The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
ANGLE plc has announced the posting of its audited Annual Report and Financial Statements for the year ending December 31, 2024, along with the Notice of its Annual General Meeting (AGM) scheduled for June 30, 2025. The AGM will be held at the Surrey Technology Centre, where shareholders can expect a business update following the formal proceedings. This announcement underscores ANGLE’s commitment to transparency and shareholder engagement, potentially impacting its market perception and stakeholder confidence.
The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
ANGLE plc announced changes to its Board, with Non-Executive Director Brian Howlett retiring after 12 years and Juliet Thompson resigning immediately. The company is evaluating its Board structure and composition moving forward, which may impact its strategic direction and governance. These changes come as ANGLE continues to focus on its core business of liquid biopsy solutions, potentially affecting its market positioning and stakeholder interests.
The most recent analyst rating on (GB:AGL) stock is a Buy with a £30.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
ANGLE plc reported a 31% increase in revenue for 2024, driven by its strategic focus on large pharmaceutical contracts, despite challenges in product sales due to regulatory changes and reduced research funding. The company has streamlined operations and secured multiple agreements with major pharma companies, positioning itself for sustainable growth and future collaborations. ANGLE’s advancements in next-generation sequencing assays and its pivotal role in groundbreaking cancer research highlight its potential impact on the industry. While the company anticipates modest revenue growth in 2025, it remains optimistic about converting ongoing discussions into substantial opportunities.
The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
ANGLE plc announced that it will release its preliminary results for the year ended 31 December 2024 on 28 May 2025. The company will host an analyst meeting at FTI Consulting in London, with a live webcast available for registered participants. This announcement highlights ANGLE’s ongoing commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.